Literature DB >> 16360885

Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity.

Baranda S Hansen1, Rehana Z Hussain, Amy E Lovett-Racke, James A Thomas, Michael K Racke.   

Abstract

Infections can trigger or exacerbate the course of Multiple Sclerosis, and both bacterial and viral agents have been implicated. These agents are recognized by host cells via pathogen-associated molecular patterns activating TLRs. We investigated the role that PAMPs play in the animal model Experimental Autoimmune Encephalomyelitis, and found various MyD88-dependent PAMPs can participate as the adjuvant to induce EAE. Studies with IRAK1-deficient mice suggest that signaling through TLRs is not required in the target organ to develop disease. This suggests that PAMPs play an important role in priming of autoreactive T cells in EAE and potentially MS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16360885     DOI: 10.1016/j.jneuroim.2005.11.006

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  20 in total

1.  Comparison of a classical Th1 bacteria versus a Th17 bacteria as adjuvant in the induction of experimental autoimmune encephalomyelitis.

Authors:  Alan J Smith; Yue Liu; Haiyan Peng; Rachel Beers; Michael K Racke; Amy E Lovett-Racke
Journal:  J Neuroimmunol       Date:  2011-06-28       Impact factor: 3.478

2.  Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling.

Authors:  Haiyan Peng; Mireia Guerau-de-Arellano; Veela B Mehta; Yuhong Yang; David J Huss; Tracey L Papenfuss; Amy E Lovett-Racke; Michael K Racke
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

3.  Different interleukin-17-secreting Toll-like receptor+ T-cell subsets are associated with disease activity in multiple sclerosis.

Authors:  Thais B Ferreira; Joana Hygino; Ana Cristina Wing; Taissa M Kasahara; Priscila M Sacramento; Solange Camargo; Fernanda Rueda; Soniza V Alves-Leon; Regina Alvarenga; Claudia Cristina Vasconcelos; Anshu Agrawal; Sudhir Gupta; Cleonice A M Bento
Journal:  Immunology       Date:  2017-12-26       Impact factor: 7.397

Review 4.  Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential.

Authors:  Mark L Hanke; Tammy Kielian
Journal:  Clin Sci (Lond)       Date:  2011-11       Impact factor: 6.124

5.  The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice.

Authors:  Beichu Guo; Elmer Y Chang; Genhong Cheng
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

6.  The innate immune response affects the development of the autoimmune response in Theiler's virus-induced demyelinating disease.

Authors:  Julie K Olson; Stephen D Miller
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

Review 7.  Corticosteroids for multiple sclerosis: I. Application for treating exacerbations.

Authors:  Elliot M Frohman; Anjali Shah; Eric Eggenberger; Luanne Metz; Robert Zivadinov; Olaf Stüve
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

8.  Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis.

Authors:  Jihong Xu; Michael K Racke; Paul D Drew
Journal:  J Neurochem       Date:  2007-12       Impact factor: 5.372

9.  Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis.

Authors:  Thomas Liggett; Anatoliy Melnikov; Shilpa Tilwalli; Qilong Yi; Haiyan Chen; Charles Replogle; Xuan Feng; Anthony Reder; Dusan Stefoski; Roumen Balabanov; Victor Levenson
Journal:  J Neurol Sci       Date:  2010-01-12       Impact factor: 3.181

10.  15-deoxy-Delta(12,14)-prostaglandin J(2) and curcumin modulate the expression of toll-like receptors 4 and 9 in autoimmune T lymphocyte.

Authors:  Wanida Chearwae; John J Bright
Journal:  J Clin Immunol       Date:  2008-05-08       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.